Did You Know?

Editor’s Picks

Latest News

Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma

Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL...

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed...

QScreen AI Completes Platform That Identifies Probable Drug a Person Has Consumed in Real Time from a Camera Alone – Targets Correctional Facilities Facing Coroner Scrutiny over Withdrawal Deaths

Patent-protected QAI Platform identifies the probable drug class - alcohol, opioids, benzodiazepines, stimulants, or cannabis from physiological camera data and...

Quad ED Under Investigation: Safe Clinician-Prescribed ED Medication Using Sildenafil, Tadalafil, Vardenafil and Apomorphine for Men

A consumer-informational overview addressing common search questions about the Quad 4-in-1 compounded sublingual ED formulation — how clinician-prescribed Sildenafil, Tadalafil,...

error: Content is protected !!